NCT02787642 2026-02-25
RADIOSARP
Institut Bergonié
Phase 1 Completed
Clinical Trials
27 trialsNCT03801369 2026-02-25
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT03025035 2026-02-06
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
Cedars-Sinai Medical Center
Phase 2 Completed
NCT03516812 2025-09-29
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
University of Washington
Phase 2 Completed
NCT04076579 2025-08-29
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT04336943 2025-08-11
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
University of Washington
Phase 2 Terminated
NCT03432897 2025-07-08
337
Brown University
Phase 2 Terminated
NCT03047135 2025-06-17
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT05405309 2025-06-03
CORONADO CLL
University of Utah
Phase 1/2 Terminated
NCT03787680 2025-03-28
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT04306367 2025-02-17
Study of Pembrolizumab and Olaparib in Bile Duct Cancer
Georgetown University
Phase 2 Completed
NCT05501548 2025-01-29
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT03314740 2025-01-10
BAROCCO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT04951492 2025-01-01
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
University of Washington
Phase 2 Terminated
NCT02953457 2024-11-19
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
Phase 2 Completed
NCT03205761 2024-10-18
COMETABreast
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT02677038 2024-10-01
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04377087 2024-08-20
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
University of Pittsburgh
Phase 2 Terminated
NCT01513174 2024-06-28
GOAL
Spanish Lung Cancer Group
Phase 1/2 Completed
NCT03810105 2024-04-09
A Study of Olaparib and Durvalumab in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT03448718 2023-11-22
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Hoosier Cancer Research Network
Phase 2 Completed
NCT04166435 2023-09-06
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
Yale University
Phase 2 Completed
NCT02576444 2022-12-28
OLAPCO
Yale University
Phase 2 Terminated
NCT02506816 2020-11-30
Polen
MedSIR
Completed
NCT01758731 2019-09-23
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
University of Colorado, Denver
Phase 1 Completed
NCT01583543 2017-05-19
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Massachusetts General Hospital
Phase 2 Completed
NCT01296763 2016-03-22
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed